Disease relevance of Lorcainide hydrochloride

• After both oral and intravenous lorcainide, ventricular tachycardia could still be induced, but the arrhythmia was slower and better tolerated hemodynamically [1].
• Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia [1].
• Lorcainide in patients with refractory ventricular tachyarrhythmia [2].
• There was 100% suppression of runs of premature beats in 11 patients after lorcainide and 99% suppression in 10 patients after lidocaine.(ABSTRACT TRUNCATED AT 250 WORDS)[3]
• The incidence of drug-induced congestive heart failure with several newer antiarrhythmic agents including encainide, ethmozine, lorcainide, mexiletine, propafenone and tocainide was determined in a group of 407 patients who underwent 1,133 drug tests [4].

High impact information on Lorcainide hydrochloride

• The mean plasma lorcainide level during a maintenance intravenous infusion was 1254 +/- 662 ng/ml compared with a lorcainide level of 562 +/- 41 ng/ml and a norlorcainide level of 1212 +/- 653 ng/ml after oral dosing [1].
• The clinical pharmacology of lidocaine congeners--review of encainide, flecainide, lorcainide and tocainide [5].
• Cardiac electrophysiology of four new antiarrhythmic drugs--encainide, flecainide, lorcainide and tocainide [6].
• Lorcainide disposition kinetics in arrhythmia patients [7].
• Electrophysiological effects of lorcainide in sinoatrial disease and in Wolff-Parkinson-White syndrome [8].

Chemical compound and disease context of Lorcainide hydrochloride

• Comparison of intravenous lorcainide with lidocaine for acute therapy of complex ventricular arrhythmias: results of a randomized study with crossover option [3].
• This study evaluated the long-term efficacy of lorcainide in suppressing chronic symptomatic PVCs, and examined the relation of arrhythmia suppression to plasma concentrations of lorcainide and norlorcainide [9].
• Thus, lorcainide compares favorably to quinidine in regard to arrhythmia suppression, but was limited in its clinical utility by CNS side effects [10].
• One hundred patients with inducible ventricular tachycardia (VT) on electrophysiologic studies underwent serial drug testing with procainamide, lidocaine and lorcainide to determine comparative efficacy [11].
• These findings suggest that, like lorcainide, SUN 1165 belongs to class Ic antiarrhythmic agents, and that SUN 1165 and lorcainide as well as disopyramide with slow and intermediate kinetics and mexiletine with fast kinetics may inhibit ventricular extrasystoles conducted at long and short range of coupling intervals, respectively [12].

Biological context of Lorcainide hydrochloride

• Lorcainide is also a class Ic antiarrhythmic drug, the bioavailability of which is nonlinear [13].
• Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent [14].
• Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide [15].
• The influence of cardiac function as measured by the left ventricular ejection fraction on the pharmacokinetic variables of a new antiarrhythmic drug, lorcainide, was investigated in 20 cardiac patients [16].
• Drug interaction between lorcainide and rifampicin [17].

Anatomical context of Lorcainide hydrochloride

• Abnormal sinus node function may be exacerbated by lorcainide treatment, however, and bundle branch block may be precipitated in patients with pre-existing conduction system disease [18].
• Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy [19].
• H-V intervals, pooled H-V intervals and QRS-width lengthened in all patients, most markedly in cases with a conduction delay below the His bundle, who had received lorcainide 2.5 mg/kg [20].
• Only minor amounts (less than 1% of the dose) of unchanged lorcainide could be recovered in urine and feces and total plasma clearance averaged 121.5 ml/min/kg [21].
• Within 2 h the decline of these concentrations was very rapid and after 8 h lorcainide could be detected only in spleen, lung and adipose tissue [21].

Associations of Lorcainide hydrochloride with other chemical compounds

• The result was compared with that of class IA (quinidine), IB (mexiletine) and IC (lorcainide) drugs to approach the subclassification of changrolin, by using standard microelectrode techniques with computer [22].
• Electrophysiological effects of a new antiarrhythmic agent, lorcainide, were studied in the isolated guinea pig ventricular myocardium and were compared with those of disopyramide; some of the experiments were also made by using the canine ventricular myocardium [23].
• Comparative effects of procainamide, tocainide and lorcainide on Na(+)-K(+)-ATPase in guinea pig heart preparations [24].
• Effect of lorcainide, a new antiarrhythmic compound, on the changes in heart rhythm induced by intravenous injection of adenosine-5'-diphosphate in rats [25].
• The pharmacokinetics and tissue distribution of the new antiarrhythmic agent lorcainide (R 15889) in rats [21].

Gene context of Lorcainide hydrochloride

• Lorcainide (R 15 889), a first review [26].
• In a blind cross-over study, 12 patients with ventricular arrhythmias (VPC's; Lown Grades II-IVB) resistant to a daily dose of quinidine 1.2 g, disopyramide 0.8 g, N-propyl-ajmaline 0.1 g were randomly given, each dose for one week, placebo (PL), mexiletine (MEX; 400, 600, 800 mg daily) and lorcainide (LOR; 200, 300, 400 mg daily) [27].

Analytical, diagnostic and therapeutic context of Lorcainide hydrochloride

• Lorcainide disposition kinetics were studied after intravenous and oral administration to patients with ventricular arrhythmias [7].
• After intravenous doses ranging from 100 to 200 mg, blood samples were drawn and plasma was analyzed for lorcainide concentration by high-pressure liquid chromatography [7].
• Seventy percent of the patients have remained on lorcainide therapy, while 47% have continued on other drug therapies started over a 20.5 +/- 3.2-month mean follow-up period [28].
• Lorcainide for high-frequency ventricular arrhythmia: preliminary results of a short-term double-blind and placebo-controlled crossover study and long-term follow-up [29].
• The electrophysiologic effects and antiarrhythmic efficacy of lorcainide were evaluated using programmed electrical stimulation (PES) in 14 patients with ventricular tachycardia (VT) refractory to conventional drug therapy [30].

References